+1 973 564 7555 [email protected]
ISO 13485:2016   MDSAP MD 1243914-1
Global Offices:
  • U.S.
  • Germany
  • Russia
    • Moscow
    • Saint Petersburg
  • Poland
  • Czech Republic
0 Items
DRG International, Inc.
  • Products
    • DRG:HYBRiD-XL®
    • Hepcidin 25 (bioactive) HS
    • Salivary ELISA Kits
    • CHROMagar
    • RUO ELISAs
    • Health Canada Registered
    • Ameritox Labs
  • Distribution
  • Newsroom
    • News
    • Media
    • Events
  • Reference Library
  • About Us
    • General Information
    • History Timeline
  • Contact Us
Select Page

Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients

Abstract Background: Intravenous (IV) iron supplementation is widely used in hemodialysis (HD) patients to treat their periodic losses. However, the ideal dose and frequency is unknown. The goal of the study is to see if a 20 mg dose of iron IV at the end of each session of HD as iron maintenance is better than the iron prior therapy. We analyze the erythropoiesis activity (EA) and functional iron (FI) after four weeks of treatment.
Methods: In 36 patients, we measure reticulocyte count and content of hemoglobin reticulocyte (CHr) as EA and FI markers, respectively, before and after the treatment. Before the study, 23 patients received another different therapy with IV iron as maintenance therapy.
Results: Reticulocyte count: 49.7 ± 23.8 × 103 before and 47.2 ± 17.2 × 103 after the treatment (p= 0.51). The CHr: 34.8 ± 3.7 pg and 34.4 ± 3.5 pg, respectively, (p= 0.35), showing an excellent correlation with the other FI markers (serum iron r = 0.6; p = 0.001; saturation transferrin r = 0.49; p = 0.004); that is not shown with the serum ferritin (r = 0.23; p = 0.192) or the hepcidin levels (r = 0.22; p = 0.251). There was not a correlation between the C-Reactive Protein, reticulocyte count, and CHr. The 13 patients who did not receive the iron prior to the study showed high FI levels, but not an increased of the serum ferritin or the serum hepcidin levels.
Conclusions: The administration of a small quantity of iron at the end of every HD session keeps the EA and the FI levels and allows reducing the iron overload administered and/or decreasing the iron stores markers in some patients.

DRG product(s) used in the study above

You can view the product details and buy it now

Hepcidin -25 (bioactive) HS Javier Deira, Silvia González-Sanchidrián, Santiago Polanco, Clarencio Cebrián, María Jiménez, Jesús Marín, Juan-Ramón Gómez-Martino, Luis Fernández-Pereira & José Tabernero

Author Information

Renal Failure Vol. 38 , Iss. 7,2016

Link: http://www.tandfonline.com/doi/full/10.1080/0886022X.2016.1184937?scroll=top&needAccess=true

by Oleg Vishnevski | May 2, 2016

 
  • Events
  • News
  • Products
  • Uncategorized

DRG International, Inc.

841 Mountain Avenue
Springfield, NJ 07081 USA

Tel: +1-973-564-7555
Fax: +1-973-564-7556

Copyright © 2022.
DRG International Inc.
All Rights Reserved.
PCI Compliance Certification

Subsidiaries

  • USA
  • Germany
  • Russia – Moscow
  • Russia – St Petersburg
  • Poland
  • Czech Republic

Support

  • Order Information
  • Troubleshooting

Shortcuts

  • Login
  • Terms of Use
  • Privacy Policy
  • Privacy Preferences
  • Privacy Policy
  • Cookie Policy
  • Facebook
  • Twitter
  • Google
  • RSS
  • linkedin
  • instagram

Designed by Walnut St. Labs